Michael Sarosdy

1.7k total citations · 1 hit paper
15 papers, 1.3k citations indexed

About

Michael Sarosdy is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Pathology and Forensic Medicine. According to data from OpenAlex, Michael Sarosdy has authored 15 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 4 papers in Surgery and 4 papers in Pathology and Forensic Medicine. Recurrent topics in Michael Sarosdy's work include Prostate Cancer Treatment and Research (9 papers), Prostate Cancer Diagnosis and Treatment (7 papers) and Hormonal and reproductive studies (2 papers). Michael Sarosdy is often cited by papers focused on Prostate Cancer Treatment and Research (9 papers), Prostate Cancer Diagnosis and Treatment (7 papers) and Hormonal and reproductive studies (2 papers). Michael Sarosdy collaborates with scholars based in United States, India and Canada. Michael Sarosdy's co-authors include Edward M. Messing, Judith Manola, Donald L. Trump, George Wilding, E. David Crawford, Mark S. Soloway, Anthony L. Patterson, Nicholas J. Vogelzang, Paul F. Schellhammer and Roohollah Sharifi and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and The Journal of Urology.

In The Last Decade

Michael Sarosdy

15 papers receiving 1.2k citations

Hit Papers

Immediate Hormonal Therapy Compared with Observation afte... 1999 2026 2008 2017 1999 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Immediate Hormonal Therapy Compared with Observation after Radical Prostatectomy and Pelvic Lymphadenectomy in Men with Node-Positive Prostate Cancer
    1999 913 citations Edward M. Messing, Judith Manola et al. New England Journal of Medicine profile →

Peers

Michael Sarosdy
Harvey B. Wolkov United States
Xavier Maldonado Spain
R. Nam Canada
F. Gómez-Veiga Spain
Maria De Santis Austria
Christine Geffriaud-Ricouard France
A.V. D’Amico United States
Kari Tuhkanen Finland
Dennis L. Broyles United States
Muriel Habibian France
Harvey B. Wolkov United States
Michael Sarosdy
Citations per year, relative to Michael Sarosdy Michael Sarosdy (= 1×) peers Harvey B. Wolkov

Countries citing papers authored by Michael Sarosdy

Since Specialization
Citations

This map shows the geographic impact of Michael Sarosdy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Sarosdy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Sarosdy more than expected).

Fields of papers citing papers by Michael Sarosdy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Sarosdy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Sarosdy. The network helps show where Michael Sarosdy may publish in the future.

Co-authorship network of co-authors of Michael Sarosdy

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Sarosdy. A scholar is included among the top collaborators of Michael Sarosdy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Sarosdy. Michael Sarosdy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Messing, Edward M., Judith Manola, Michael Sarosdy, et al.. (2004). Immediate hormonal therapy versus observation after radical prostatectomy and pelvic lymphadenectomy for node positive prostate cancer: At 10 years results of EST3886. Journal of Clinical Oncology. 22(14_suppl). 4570–4570. 39 indexed citations
2.
Messing, Edward M., Judith Manola, Michael Sarosdy, et al.. (2004). Immediate hormonal therapy versus observation after radical prostatectomy and pelvic lymphadenectomy for node positive prostate cancer: At 10 years results of EST3886. Journal of Clinical Oncology. 22(14_suppl). 4570–4570. 4 indexed citations
3.
Plaetke, Rosemarie, Ian M. Thompson, Michael Sarosdy, et al.. (2002). Genetic fieldwork for hereditary prostate cancer studies. Urologic Oncology Seminars and Original Investigations. 7(1). 19–27. 5 indexed citations
4.
Arar, Nedal H., Ian M. Thompson, Michael Sarosdy, et al.. (2000). Risk perceptions among patients and their relatives regarding prostate cancer and its heredity. Prostate Cancer and Prostatic Diseases. 3(3). 176–185. 8 indexed citations
5.
Šarić, Tomo, Zoran Brkanac, Dean A. Troyer, et al.. (1999). Genetic pattern of prostate cancer progression. International Journal of Cancer. 81(2). 219–224. 61 indexed citations
6.
Messing, Edward M., Judith Manola, Michael Sarosdy, et al.. (1999). Immediate Hormonal Therapy Compared with Observation after Radical Prostatectomy and Pelvic Lymphadenectomy in Men with Node-Positive Prostate Cancer. New England Journal of Medicine. 341(24). 1781–1788. 913 indexed citations breakdown →
7.
Messing, Edward M., Judith Manola, George Wilding, et al.. (1999). IMMEDIATE HORMONAL THERAPY VS. OBSERVATION FOR NODE POSITIVE PROSTATE CANCER FOLLOWING RADICAL PROSTATECTOMY AND PELVIC LYMPHADENECTOMY. The Journal of Urology. 175–175. 19 indexed citations
8.
Xiao, Han, Madhu Mazumdar, Dean F. Bajorin, et al.. (1997). Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin.. Journal of Clinical Oncology. 15(7). 2553–2558. 43 indexed citations
9.
10.
Soloway, Mark S., Paul F. Schellhammer, P. Venner, et al.. (1996). A Controlled Trial of Casodex™(Bicalutamide) vs. Flutamide,Each in Combination with LuteinisingHormone-Releasing HormoneAnalogue Therapy in Patients withAdvanced Prostate Cancer. European Urology. 29(2). 105–109. 20 indexed citations
11.
Schellhammer, Paul F., Anthony L. Patterson, Roohollah Sharifi, et al.. (1995). A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Urology. 45(5). 745–752. 97 indexed citations
12.
Sarosdy, Michael. (1992). High-dose versus low-dose intravesical interferon-α2b in the treatment of carcinoma in situ. Anti-Cancer Drugs. 3. 13–18. 10 indexed citations
13.
Sharifi, Roohollah, Migyung Lee, Damon G. Lamb, et al.. (1991). Phase I-II evaluation of intravesical novantrone (mitoxantrone) in superficial bladder cancer. Anti-Cancer Drugs. 2(2). 153–158. 5 indexed citations
14.
15.
Lamm, Donald L., et al.. (1982). Androgen priming and cytotoxic chemotherapy in advanced prostatic cancer. Cancer Chemotherapy and Pharmacology. 8(3). 261–5. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Harvey B. Wolkov Breakdown of academic impact, for papers by Xavier Maldonado Breakdown of academic impact, for papers by R. Nam Breakdown of academic impact, for papers by F. Gómez-Veiga Breakdown of academic impact, for papers by Maria De Santis Breakdown of academic impact, for papers by Christine Geffriaud-Ricouard Breakdown of academic impact, for papers by A.V. D’Amico Breakdown of academic impact, for papers by Kari Tuhkanen Breakdown of academic impact, for papers by Dennis L. Broyles Breakdown of academic impact, for papers by Muriel Habibian
Rankless by CCL
2026